FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States.”
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Metastron™, with Jubilant Radiopharma for the United States market. Jubilant Radiopharma is an industry leading pharmaceutical company specializing in nuclear medicine focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents on a global scale.
Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.
Jubilant Radiopharma is an industry leading radiopharmaceutical company focused on developing, manufacturing, commercializing and distributing high quality and sustainable diagnostic and therapeutic agents for the sole purpose of Improving Lives Through Nuclear Medicine on a global scale.
Cancer is ranked among the top causes of death globally, and recent data indicates that the number of cancer related cases is only expected to rise. As a result, the global cancer therapeutics market is projected to grow. According to a research by Allied Market Research, the global cancer therapeutics market size was valued at USD 98,900 Million in 2018 and is expected to reach USD 180,193 Million by 2026 while registering a CAGR of 7.7% from 2019 to 2026. Among the many factors influencing the cancer therapeutics segment is the increase in cancer prevalence, growth of the geriatric population, surge in collaboration between pharmaceutical companies and the rise in cancer research. However, the high cost linked with oncology drug development and with adverse effects associated with cancer therapeutics are restraining the market growth. Yet, it is the upsurge in demand for personalized medicine and the potential of developing nations that is expected to provide new opportunities for the many market players in the future. In addition, an increase in competition and continuous technological advancements have led to improved product portfolios and more often product approvals.
To illustrate the dire need for new cancer therapeutic developments, the National Cancer Institute provided revealing statistics. The institute estimated that 1.73 million people in the U.S. were affected by cancer in 2018. Additionally, the report also suggested that 609,640 people passed away due to cancer in the same year. Overall, cancer research has accelerated over the past several decades. And typically, most cancer patients undergo various types of therapies such as chemotherapy or radiotherapy. Generally, these therapies use stimulants such as anti-cancer drugs or radiation to eradicate cancerous cells. However, the acceleration of the cancer technology market has introduced new procedures such as personalized treatments. Notably, formalin-fixed paraffin-embedded (FFPE) has become a crucial part of cancer research in labs in recent years. FFPE is a form of preservation and preparation for biopsy specimens that aid in the examination, experimental research, and diagnostic/drug development, according to Biochain. A tissue sample is first preserved by fixing it in formaldehyde to preserve the proteins and vital structures within the tissue. These tissues are then frequently used in immunohistochemistry (IHC). The information provided from IHC can aid doctors in spotting signs of diseases such as cancer or Alzheimer’s. Now, as the cancer treatment industry continues to advance, medical researchers are continuing to develop treatments and therapies that will effectively eliminate or limit the condition in patients. And with the number of cases emerging around the world, the biotechnology market is primed to witnessed substantial growth. “I see major advances in saving lives from cancer in the next 10 years by eliminating cancer health disparities. By implementing our research findings and changing how we organize the care to patients, we can reduce and eliminate cancer health disparities,” according to Karen M. Freund, M.D., M.P.H., Tufts Medical. ” We have shown through research that providing additional support to vulnerable patients and to their physicians, to provide education, support, and address the unique barriers they face, we can provide all patients the best care and best hope for a cure.”
For more information, please visit: Q BioMed Inc.
For more corporate news on Q BioMed Inc., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.